Patents by Inventor Christine M. Posavad

Christine M. Posavad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunologically significant herpes simplex virus antigens and methods for using same
    Patent number: 7037509
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: May 2, 2006
    Assignees: University of Washington, Fred Hutchinson Cancer Research Center, Corixa Corporation
    Inventors: David M. Koelle, Nancy A. Hosken, Christine M. Posavad, Hongbo Chen, Patrick McGowan
  • Immunologically significant herpes simplex virus antigens and methods for identifying and using same
    Patent number: 6962709
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: November 8, 2005
    Assignee: University of Washington, Fred Hutchinson Cancer Research Center
    Inventors: David M. Koelle, Hongbo Chen, Lawrence Corey, Nancy Ann Hosken, Patrick McGowan, Steven P. Fling, Christine M. Posavad
  • Immunologically significant herpes simplex virus antigens and methods for using same
    Publication number: 20040241182
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: June 30, 2004
    Publication date: December 2, 2004
    Inventors: David M. Koelle, Nancy A. Hosken, Christine M. Posavad, Hongbo Chen, Patrick McGowan
  • Immunologically significant herpes simplex virus antigens and methods for using same
    Patent number: 6814969
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: November 9, 2004
    Assignee: University of Washington
    Inventors: David M. Koelle, Nancy A. Hosken, Christine M. Posavad, Hongbo Chen, Patrick McGowan
  • Immunologically significant herpes simplex virus antigens and methods for using same
    Publication number: 20030190324
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: July 31, 2002
    Publication date: October 9, 2003
    Inventors: David M. Koelle, Nancy A. Hosken, Christine M. Posavad, Hongbo Chen, Patrick McGowan
  • Immunologically significant herpes simplex virus antigens and methods for identifying and using same
    Publication number: 20020155122
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: April 5, 2002
    Publication date: October 24, 2002
    Applicant: University of Washington
    Inventors: David M. Koelle, Hongbo Chen, Lawrence Corey, Nancy Ann Hosken, Patrick McGowan, Steven P. Fling, Christine M. Posavad
  • Immunologically significant herpes simplex virus antigens and methods for identifying and using same
    Patent number: 6413518
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: July 2, 2002
    Assignees: University of Washington, Fred Hutchinson Cancer Research Center, Corixa Corporation
    Inventors: David M. Koelle, Hongbo Chen, Lawrence Corey, Nancy Ann Hosken, Patrick McGowan, Steven P. Fling, Christine M. Posavad